T cells play a crucial role in the immune system by patrolling the body to eliminate infected or cancerous cells. However, cancer cells can evade detection and destruction by T cells, posing a challenge for targeted immunotherapies. Researchers at the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, led by Dr. Armin Rehm and Dr. Uta Höpken, have identified a mechanism involving the EBAG9 gene that allows tumor cells to evade immune responses. By inhibiting the secretion of enzymes in T cells, EBAG9 protects cancer cells from being killed by the immune system, highlighting the need to overcome this immune evasion strategy.
Checkpoint inhibitors have been developed to counteract cancer cells’ ability to evade immune surveillance. These inhibitors prevent cancer cells from deceiving T cells into ignoring their presence. However, EBAG9 provides an additional defense mechanism for cancer cells, inhibiting immune cells and preventing them from releasing substances that could harm the cancer cells. The researchers at MDC have demonstrated in mouse models that by silencing the EBAG9 gene, the immune response against cancer can be strengthened, leading to a more effective long-term immune response against tumors.
Studies have shown that EBAG9 not only inhibits T cells but also influences the immune response to cancer differently from the response to infections. T cells develop a memory of harmful structures on infected or cancerous cells, enabling a faster and more effective response upon subsequent encounters. By employing single-cell RNA sequencing and bioinformatic techniques, researchers have confirmed the inhibitory role of EBAG9 on T cell responses and highlighted the distinct immune responses triggered by cancer and infections.
In preclinical studies, disabling the EBAG9 gene resulted in uninhibited T cells that efficiently targeted and eliminated tumor cells early on, providing lasting protection against cancer. This discovery has paved the way for the development of chimeric antigen receptor (CAR) T cells without EBAG9 as a potential immunotherapy for leukemia. CAR T cells are engineered to recognize and destroy tumor cells, offering a personalized treatment approach. The researchers anticipate that CAR T cells without EBAG9 could enhance the effectiveness of this therapy, potentially leading to more efficient treatments and even cures for leukemia and lymphoma.
The findings of this research, published in JCI Insight, offer valuable insights into the mechanisms of immune evasion employed by cancer cells and the potential strategies to enhance the immune response against tumors. By targeting EBAG9 and developing CAR T cells without this inhibitory factor, researchers aim to revolutionize immunotherapy for cancer treatment. While further studies are needed to advance this approach to clinical trials, the prospect of improving outcomes for patients with leukemia and lymphoma through innovative immunotherapies is promising.
Key Takeaways:
1. EBAG9 gene allows tumor cells to evade immune responses by inhibiting T cell function, highlighting the need to overcome this immune evasion strategy.
2. Silencing the EBAG9 gene in mouse models has shown to strengthen the immune response against cancer and slow tumor growth, offering potential for long-term protection against tumors.
3. Developing CAR T cells without EBAG9 as an immunotherapy for leukemia could lead to more effective treatments and potential cures, revolutionizing cancer treatment approaches.
Tags: secretion, immunotherapy
Read more on mdc-berlin.de